An Open-Label, Multi-Center Phase 2 study to Assess the Safety and Efficacy of Burixafor (GPC-100) and Propranolol with G-CSF for the Mobilization of Hematopoietic Progenitor Cells in Patients with Multiple Myeloma

Authors
Category Primary study
ConferenceTransplantation and Cellular Therapy
Year 2026
This article has no abstract
Epistemonikos ID: b113917af9c6a07956b60033aacc3e100565cc90
First added on: Feb 14, 2026